Sales grew 9% to $28.4 million. That was well ahead of the $25.9 million that analysts had projected.
Operating income surged 14% to $7.2 million.
Net income grew 41% to $6 million, or $0.30 per share. That figure blew past the $0.20 that Wall Street was expecting.
The board of directors approved a 21% increase to the quarterly dividend and gave the thumbs-up to repurchasing $10 million shares of common stock.
Zooming out to the full year, here's how the company performed in 2018:
Revenue jumped 5% to $105.6 million. That was solidly ahead of the $103 million that was expected.
Net income grew 34% to $22.9 million. However, the bulk of the increase is attributable to one-time gains on business divestitures and acquisitions.
EPS jumped 31% to $1.13. This was comfortably above the $1.04 that market watchers were expecting.
finance.yahoo.com/news/why-lemaitre-vascular-soaring-161800004.html?.tsrc=rss
Operating income surged 14% to $7.2 million.
Net income grew 41% to $6 million, or $0.30 per share. That figure blew past the $0.20 that Wall Street was expecting.
The board of directors approved a 21% increase to the quarterly dividend and gave the thumbs-up to repurchasing $10 million shares of common stock.
Zooming out to the full year, here's how the company performed in 2018:
Revenue jumped 5% to $105.6 million. That was solidly ahead of the $103 million that was expected.
Net income grew 34% to $22.9 million. However, the bulk of the increase is attributable to one-time gains on business divestitures and acquisitions.
EPS jumped 31% to $1.13. This was comfortably above the $1.04 that market watchers were expecting.
finance.yahoo.com/news/why-lemaitre-vascular-soaring-161800004.html?.tsrc=rss
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.